{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:56:17Z","timestamp":1751403377999,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The glucagon stimulation test involves the peptide intramuscular or subcutaneous administration for the diagnosis of hypopituitarism. To date, no data are available regarding its intranasal formulation. Our study intended to investigate the role of intranasal glucagon as a potential stimulus test for the evaluation of the corticotropic, somatotropic, and antidiuretic axes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Non-randomized, single-blinded, cross-over study including 10 healthy subjects (50% women).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All participants underwent 2 days of testing, and intranasal glucagon or placebo was administered. At baseline, every 15\u2032 up to +90\u2032, and then every 30\u2032 up to +180\u2032, a blood sample was taken for adrenocorticotropic hormone (ACTH), cortisol, growth hormone (GH), copeptin, glucose, insulin, sodium, potassium, and plasma osmolarity. At baseline and at the end of the test, urinary osmolarity was evaluated as well.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After administration of both glucagon and placebo, ACTH and cortisol values decreased progressively (P &amp;lt; 0.001), but in the drug group, the reduction in cortisol was less accentuated up to +90\u2032 (P &amp;lt; 0.05). Growth hormone values decreased after placebo administration (P &amp;lt; 0.001); on the other hand, after glucagon, an increasing, yet non-significant trend was observed (P = 0.096) with the difference between the two groups evident starting from +120\u2032 onwards (P &amp;lt; 0.005). The placebo administration led to a reduction of copeptin, while its stability was observed after glucagon administration. Six subjects developed hypokalemia (ie, potassium &amp;lt;3.5\u2005mmol\/L) post-glucagon, with the nadir at 45\u2032 (3.6 [3.2-3.8] mmol\/L) significantly correlated with the immediate post-glycemic rise insulin peak (Spearman's rho \u22120.719; P = 0.019). No significant differences were observed compared to the other analytes tested.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intranasal glucagon administration is not an effective stimulus for hypophyseal secretion. Hypokalemia secondary to hyperinsulinemic rebound appears to be a frequent complication of its acute administration.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ejendo\/lvad019","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T17:02:31Z","timestamp":1675962151000},"page":"258-265","source":"Crossref","is-referenced-by-count":10,"title":["Adrenocortical, somatotropic, and antidiuretic response to nasal glucagon in healthy subjects"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-8586","authenticated-orcid":false,"given":"Emanuele","family":"Varaldo","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Bioletto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cuboni","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzia","family":"Prencipe","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bona","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Barale","sequence":"additional","affiliation":[{"name":"Oncological Endocrinology Unit, Department of Oncology, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Grottoli","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro Maria","family":"Berton","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Gasco","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin , Turin 10126 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"issue":"11","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12902-016-0117-7","article-title":"How should we interrogate the hypothalamic-pituitary-adrenal axis in patients with suspected hypopituitarism?","volume":"16","author":"Garrahy","year":"2016","journal-title":"BMC Endocr Disord."},{"issue":"3","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40618-022-01926-z","article-title":"Development and internal validation of a predictive score for the diagnosis of central adrenal insufficiency when morning cortisol is in the grey zone","volume":"46","author":"Bioletto","year":"2023","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000508103","article-title":"The cut-off limits of growth hormone response to the insulin tolerance test related to body mass index for the diagnosis of adult growth hormone deficiency","volume":"111","author":"Gasco","year":"2021","journal-title":"Neuroendocrinology"},{"key":"2023032510162898800_","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.737947","article-title":"Development and internal validation of a predictive model for adult GH deficiency prior to stimulation tests","volume":"12","author":"Bioletto","year":"2021","journal-title":"Front Endocrinol"},{"issue":"3","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12020-017-1356-8","article-title":"Glucagon stimulation test: has its time come?","volume":"57","author":"Boguszewski","year":"2017","journal-title":"Endocrine"},{"issue":"5","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/eje.0.1430601","article-title":"Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans","volume":"143","author":"Arvat","year":"2000","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ghir.2008.06.002","article-title":"Relationship between GH response and glycemic fluctuations in the glucagon stimulation test","volume":"19","author":"Giuffrida","year":"2009","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1530\/EJE-09-0824","article-title":"Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery","volume":"162","author":"Berg","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11102-012-0407-7","article-title":"Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults","volume":"16","author":"Yuen","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-015-0783-7","article-title":"Copeptin under glucagon stimulation","volume":"52","author":"Lewandowski","year":"2016","journal-title":"Endocrine"},{"issue":"11","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/biomedicines10112857","article-title":"Limited role of endogenous vasopressin\/copeptin in stimulation of ACTH-cortisol secretion during glucagon stimulation test in humans","volume":"10","author":"Malicka","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/EJE-22-0033","article-title":"Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind, randomized, placebo-controlled study","volume":"187","author":"Atila","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/dom.13134","article-title":"Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: a randomized clinical trial","volume":"20","author":"Guzman","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/dc15-1606","article-title":"Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"issue":"1 Pt 1","key":"2023032510162898800_","first-page":"E107","article-title":"Females secrete growth hormone with more process irregularity than males in both humans and rats","volume":"270","author":"Pincus","year":"1996","journal-title":"Am J Physiol"},{"issue":"4","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2265.2001.01169.x","article-title":"An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease","volume":"54","author":"Leong","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"11","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/BF03347790","article-title":"Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity","volume":"17","author":"Ghigo","year":"1994","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF00281818","article-title":"Influence of glucagon on plasma levels of potassium in man","volume":"19","author":"Massara","year":"1980","journal-title":"Diabetologia"},{"issue":"6","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ki.1977.62","article-title":"Role of glucoregulatory hormones in potassium homeostasis","volume":"11","author":"Knochel","year":"1977","journal-title":"Kidney Int"},{"issue":"2","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc15-1498","article-title":"Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study","volume":"39","author":"Rickels","year":"2016","journal-title":"Diabetes Care"},{"issue":"12","key":"2023032510162898800_","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1210\/jc.2014-2830","article-title":"Overweight\/obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency","volume":"99","author":"Dichtel","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad019\/49144768\/lvad019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/3\/258\/49630873\/lvad019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/3\/258\/49630873\/lvad019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:39:34Z","timestamp":1701862774000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/188\/3\/258\/7033311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad019","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"type":"print","value":"0804-4643"},{"type":"electronic","value":"1479-683X"}],"subject":[],"published-other":{"date-parts":[[2023,3,2]]},"published":{"date-parts":[[2023,2,9]]}}}